CHEK1 and neuroblastoma: To further explore differences in sensitivity to CHK1 inhibition and to validate our observation that 11q deletion is correlated with sensitivity to CHK1 inhibition, we tested prexasertib in a panel of 12 NB cell lines (outlined in Figure 2A) that were selected based on the presence or absence of 11q loss as determined by WGS.